Percutaneous transluminal angioplasty treatment of renal transplant artery stenosis.

Since June 1979, percutaneous transluminal angioplasty (PTA) has been the procedure of choice for renal transplant artery stenosis (RTAS) at the Hospital of the University of Pennsylvania. Of 241 renal allograft recipients, 17 (7%) when studied by arteriogram because of suspected RTAS proved to have significant stenosis (the mean reduction in luminal width for the group being 68%) and underwent PTA. RTAS was equally prevalent in cadaver and related kidney allografts and was no less common in HLA-identical related donor grafts, arguing against the importance of immune factors in etiology. RTAS was equally prevalent whether the anastomotic technique was end to end or end to side. However, when RTAS occurred after end to side anastomoses, it was usually postanastomotic. Fifteen of 17 of the attempts at dilation by PTA were successful by angiographic analysis. Thirteen of the 15 successfully dilated patients had long-term allograft survival and in all of these instances blood pressure (BP) was decreased after PTA. After a mean of 67 weeks, BP decreased from a systolic of 184 +/- 24 mm Hg pre-PTA to 135 +/- 15 mm Hg (P less than 0.001) and from a diastolic of 115 +/- 10 mm Hg pre-PTA to 87 +/- 11 mm Hg (P less than 0.001). The majority of patients continue to require antihypertensive drugs but in a less vigorous regimen than pre-PTA. Serum creatinine level fell following PTA from 1.9 +/- 0.6 to 1.7 +/- 0.5 mg/100 ml (P less than 0.01). Repeat angiographic study was done in nine patients, an average of 61 weeks after PTA, and no recurrent RTAS was identified. Three minor complications of PTA occurred but none led to long-term sequelae. Thus, we believe PTA of RTAS is relatively safe, carrying less mortality and morbidity than operative treatment, and is capable of improving BP control and renal allograft function.

Treatment of acute vascular occlusions with intra-arterial urokinase.

This study reviewed 57 patients with 71 vascular occlusions treated with urokinase from 1985 to 1988. Of these patients, 89% were candidates for urgent surgery. Total clot lysis was achieved in 73% of cases. The success rate rose with increasing experience (p less than 0.05), and recent occlusions had more favorable outcomes than older ones (p less than 0.05). The length and type of occluded conduit (graft or vessel), age, sex, other medical conditions, and concurrent use of heparin had no influence on success. Of 18 cases successfully lysed and not subjected to any adjunctive therapy directed at the cause of occlusion, 9 (50%) reoccluded within 1 to 88 days (mean: 25 days). Cases successfully treated with thrombolysis and surgery or dilation of the causative stenosis had poor 1-year patencies: 17%, 20%, and 55% for vein grafts, prosthetic grafts, and native arteries, respectively. With additional urokinase treatments, surgical operations, and percutaneous procedures, 1-year patencies were 22%, 45%, and 65%, respectively.

Stenting of proximal venous obstructions to maintain hemodialysis access.

PURPOSE: The purpose of the study was to evaluate the efficacy of stenting central venous obstructions in patients dependent on hemodialysis to preserve or restore central venous patency and allow for continued hemodialysis from the affected side. METHODS: Twenty-five self-expanding (17) and balloon-expandable (8) stainless steel stents were deployed in 19 patients with end-stage renal disease and central venous stenosis or occlusion. Nineteen lesions were treated: 11 subclavian and eight innominate. Twenty-two stents were initially implanted. RESULTS: Stent deployment was successful in all cases and immediately remedied the underlying cause of venous hypertension. Follow-up at up to 17 months revealed three deaths from unrelated causes, one occlusion at 3.25 months, and three restenoses at 16 days, 2.5 and 5 months, respectively, with successful implantation of three additional stents for a primary central patency rate of 68% (+/- 14%) and secondary central patency rate of 93% (+/- 7%). CONCLUSIONS: Stenting of subclavian and innominate venous stenoses and occlusions effectively corrected the underlying lesions responsible for disturbed hemodynamics and, in most cases, prolonged available hemodialysis access from the affected side. Stents seem to be valuable adjuncts in the management of failing hemodialysis access due to central venous stenosis or occlusion.

A balloon-expandable intravascular stent for obliterating experimental aortic dissection.

Acute aortic dissection is a life-threatening condition. Aggressive hypotensive drug therapy is the initial treatment of choice, although emergent surgical intervention is often warranted. We evaluated the efficacy of a balloon-expandable intravascular stent for the internal obliteration of aortic dissection. It is a flexible, continuous, complex coil cut to the length needed at the time of insertion. It can be positioned in curved vessels, including the aortic arch. The stent was inserted in the thoracic and abdominal aorta of 12 dogs (group I). Six weeks after implantation the dogs underwent angiography and the stents were explanted for light and scanning electron microscopy. There were no instances of stent migration or change in configuration. The aortas did not rupture. All branch vessels remained patent. Light and scanning electron microscopy illustrated neointimal incorporation into the vascular wall except at orifices. Thoracic dissections were created surgically in an additional 24 mongrel dogs. Twelve dogs received stents immediately after creation of the dissection (group II). All 12 dissections were obliterated. Twelve dogs were allowed to recover after creation of the dissection to observe the natural history of that lesion (group III). Within 1 week, in group III, there were three deaths because of aortic rupture; eight dissections persisted, and one resealed spontaneously. Stents were placed in the eight persistent dissections. All eight dissections were obliterated. In both groups, after 6 weeks of stent placement, aortography was repeated, and stents were explanted for light and scanning electron microscopy. There were no instances of rupture. All branch vessels remained patent with no evidence of thrombosis. We conclude that because of its unique characteristics, the stent effectively obliterates the false lumen of experimental acute aortic dissections without occlusing side branches, damaging the aorta, or inducing thrombosis.